1. Home
  2. ANL vs SBSI Comparison

ANL vs SBSI Comparison

Compare ANL & SBSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.62

Market Cap

998.8M

Sector

N/A

ML Signal

HOLD

Logo Southside Bancshares Inc.

SBSI

Southside Bancshares Inc.

HOLD

Current Price

$32.00

Market Cap

950.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
SBSI
Founded
2004
1960
Country
Singapore
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
950.3M
IPO Year
2022
1995

Fundamental Metrics

Financial Performance
Metric
ANL
SBSI
Price
$10.62
$32.00
Analyst Decision
Strong Buy
Hold
Analyst Count
7
5
Target Price
$29.50
★ $34.00
AVG Volume (30 Days)
★ 319.9K
115.6K
Earning Date
08-14-2026
10-29-2026
Dividend Yield
N/A
★ 4.66%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 1.68
Revenue
N/A
N/A
Revenue This Year
$243.83
$4.65
Revenue Next Year
N/A
$3.15
P/E Ratio
★ N/A
$18.90
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$27.59
52 Week High
$17.25
$36.20

Technical Indicators

Market Signals
Indicator
ANL
SBSI
Relative Strength Index (RSI) 36.44 63.92
Support Level $8.96 $31.62
Resistance Level $12.49 $33.34
Average True Range (ATR) 1.30 0.53
MACD -0.29 0.24
Stochastic Oscillator 5.98 90.36

Price Performance

Historical Comparison
ANL
SBSI

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About SBSI Southside Bancshares Inc.

Southside Bancshares Inc is a bank holding company. Through its subsidiary, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.

Share on Social Networks: